<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02306187</url>
  </required_header>
  <id_info>
    <org_study_id>BP-ED study 2014</org_study_id>
    <nct_id>NCT02306187</nct_id>
  </id_info>
  <brief_title>The Effectiveness of Eldecalcitol in the Bisphosphonate Non-respondered-patients With Osteoporosis</brief_title>
  <official_title>The Effectiveness of Eldecalcitol in the Osteoporotic Patients Who Are Bisphosphonate Non-responders After Long-term Bisphosphonate Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shinshu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shinshu University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the patients with osteoporosis, bisphosphonates (BPs) are a golden standard treatment.
      However, the bone turnover markers or the bone mineral density (BMD) are not improved in some
      osteoporotic patients even though they have taken BPs and alfacalcidol more than several
      years. In those case, the investigators better off prescribing BPs and Eldecalcitol, instead
      of BPs and Alfacalcitol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alfacalcitol and Eldecalcitol are the similar vitamin D drugs. However, Eldecalcitol is an
      improved vitamin D drug than Alfacalcitol. Therefore, we investigate the effectiveness of
      Eldecalcitol in this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with bone turnover markers as a Measure of bone quality</measure>
    <time_frame>At 4 months after the initial treatment</time_frame>
    <description>Bone formation and bone absorption markers will be evaluated at each time point</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with bone turnover markers as a Measure of bone quality</measure>
    <time_frame>At 1 year after the initial treatment</time_frame>
    <description>Bone formation and bone absorption markers will be evaluated at each time point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with bone mineral density as a Measure of bone quality</measure>
    <time_frame>At 4 months after the initial treatment</time_frame>
    <description>Bone mineral density will be evaluated at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with bone mineral density as a Measure of bone quality</measure>
    <time_frame>At 1 year after the initial treatment</time_frame>
    <description>Bone mineral density will be evaluated at each time point</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Non-Alfacaocidol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ahead of Eldecalcitol treatment, this group has not taken Alfacaocidol before. Eldecalcitol: the commercial name is Edirol We prescribe Edirol 0.5 or 0.75ug per day into each patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alfacalcidol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ahead of Eldecalcitol treatment, this group has taken Alfacaocidol before. Eldecalcitol: the commercial name is Edirol We prescribe Edirol 0.5 or 0.75ug per day into each patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edirol</intervention_name>
    <description>Edirol 0.5 or 0.75ug once every day oral treatment for at least 1 year after initial visit.</description>
    <arm_group_label>Non-Alfacaocidol</arm_group_label>
    <arm_group_label>Alfacalcidol</arm_group_label>
    <other_name>Eldecalcitol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Osteoporosis

          -  Must be able to swallow tablets

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yukio Nakamura, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shinshu University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yukio Nakamura, MD, PhD</last_name>
    <phone>+81-263-37-2659</phone>
    <email>yxn14@aol.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yukio Nakamura</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <zip>3908621</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yukio Nakamura, MD, PhD</last_name>
      <phone>+81-263-37-2659</phone>
      <email>yxn14@aol.jp</email>
    </contact>
    <investigator>
      <last_name>Yukio Nakamura, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2014</study_first_submitted>
  <study_first_submitted_qc>November 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2014</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shinshu University</investigator_affiliation>
    <investigator_full_name>Yukio Nakamura</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>The changes of bone mineral density and bone turnover markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphosphonates</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

